A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2023-06-18
Adverse events
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-13 (study day 98); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-01-24 (study day 201); relationship: N
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-05-16 (study day 314); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-05-21 (study day 319); relationship: N
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-06-01 (study day 330); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-06-19 (study day 348); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-06-22 (study day 351); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-07-24 (study day 383); relationship: N
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-08-04 (study day 394); relationship: not assessed
Data queries
No data queries.